News

Aug 14, 2025

Another Breakthrough in Anti-HBV Drugs: Zhimeng Biopharma Achieved the Key Milestone of First Patient First Dose in the Pivotal Phase III Trial for ZM-H1505R

Aug 12, 2025

Zhimeng Biopharma Successfully Holds National Investigator Meeting for Phase III Trial of ZM-H1505R

Jul 09, 2025

Zhimeng Biopharma’s Next-Generation KCNQ2/3 Potassium Channel Opener Receives Clinical Trial Approval for ALS Phase 2/3 Study

Jun 05, 2025

Zhimeng’s Innovative HBV Core Protein-Targeted Drug Reached Agreement with CDE for Initiating the Phase 3 Clinical Trial

Oct 19, 2023

Zhimeng Biopharma CB03 Received Orphan Drug Designation from the US FDA - A Potassium Ion Channel Opener for Amyotrophic Lateral Sclerosis

Feb 01, 2023

Zhimeng Biopharma Entered into A Global Exclusive Licensing Agreement with GlaxoSmithKline in HBV

Dec 27, 2022

Zhimeng Biopharma Announces Dosing of First Subject in Phase II Clinical Trial of Its Novel HBV Capsid Assembly Modulator

May 12, 2022

Zhimeng Biopharma Announces Dosing of First Subject of Its Novel Antiepileptic Drug Candidate CB03 in First-in-Human Phase I Clinical Trial

Apr 02, 2022

Zhimeng Biopharma Announces Dosing of First Subject in First-in-Human Phase I Clinical Trial of CB06

Dec 17, 2021

Zhimeng Biopharma Announces FDA Approval of its Investigational New Drug (IND) Application for CB06-036

prev
1
2
3
next

Get in touch

Contact Us About Us Leadership Team Scientific Advisors